Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 studyMarina Elena Cazzaniga, Massimiliano Mazza, G. Pinotti et al.|The Breast|2019Cited by 58
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 studyMarina Elena Cazzaniga, I. Vallini, Emilia Montagna et al.|Breast Cancer Research and Treatment|2021Cited by 17
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patientsB. Trevisan, Francesca Fulvia Pepe, I. Vallini et al.|Scientific Reports|2023Cited by 5
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Elena Cazzaniga, Valter Torri, Claudio Verusio et al.|Oncotarget|2018Cited by 4